5-Hydroxymethylcytosine is a predominantly stable DNA modification by Bachman, Martin et al.
 1 
Title 
5-Hydroxymethylcytosine is a predominantly stable DNA modification 
 
Authors 
Martin Bachman1,2, Santiago Uribe-Lewis2, Xiaoping Yang2, Michael Williams2, 
Adele Murrell2,3, Shankar Balasubramanian1,2,* 
 
Affiliations 
1Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, 
UK 
2Cancer Research UK Cambridge Institute, University of Cambridge, 
Cambridge CB2 0RE, UK 
3Centre for Regenerative Medicine, Department of Biology and Biochemistry, 
University of Bath, Bath BA2 7AY, UK 
*E-mail: sb10031@cam.ac.uk 
 
Abstract 
5-Hydroxymethylcytosine (hmC) is an oxidation product of 5-methylcytosine 
(mC) present in DNA of most mammalian cells. Reduction of hmC levels in 
DNA is a hallmark of cancers. Elucidating the dynamics of this oxidation 
reaction and the lifetime of hmC in DNA is fundamental to understanding hmC 
function. Using stable isotope labeling of cytosine derivatives in the DNA of 
mammalian cells and ultrasensitive tandem liquid-chromatography mass 
spectrometry (LCMS), we show that the majority of hmC is a stable 
modification, as opposed to a transient intermediate. In contrast with DNA 
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methylation, which occurs immediately during replication, hmC forms slowly 
over the first 30 h following DNA synthesis. Isotopic labeling of DNA in mouse 
tissues confirmed the stability of hmC in vivo and demonstrated a relationship 
between global levels of hmC and cell proliferation. These insights have 
important implications for understanding the states of chemically modified 
DNA bases in health and disease. 
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Methylation of cytosine (C) at C-5 to form 5-methylcytosine (mC), by DNA 
methyltransferase enzymes, is an important epigenetic DNA modification that 
is essential for development, normal function and disease in all mammals1. In 
2009, it was robustly demonstrated that 5mC could be enzymatically oxidized 
to 5-hydroxymethylcytosine (hmC)2,3. The initial discoveries were made in 
genomic DNA isolated from mouse brain and embryonic stem (mES) cell DNA, 
but hmC has subsequently been detected in all mammalian tissues4. In 
contrast with global DNA methylation levels which are stable across tissues, 
the levels of hmC are highly tissue-specific, ranging between 0.03 % of all 
cytosines in the spleen and 0.7 % in the brain4, and are reduced up to 8-fold 
in cancer tissues relative to healthy ones5-8. The oxidation of mC to hmC is 
carried out by the ten-eleven translocation (TET) enzymes3,9, iron and 2-
oxoglutarate dependent dioxygenases, which are also able to further oxidize 
hmC to 5-formylcytosine (fC) and 5-carboxycytosine (caC)10,11. A number of 
pathways for the removal of the methyl group from mC via hmC have been 
suggested and validated in vitro, thus proposing hmC as an intermediate of 
DNA demethylation12. However, given that hmC binds to specific regulatory 
proteins13-15 and that it is mainly present at actively transcribed genes13,16-19, it 
appears that hmC may convey regulatory functions and be an epigenetic 
mark in its own right. 
While the study of hmC has been rapidly growing during the past 5 years12 
many fundamentally important questions remain unanswered20. Herein we 
have focused on the metabolism of C to mC and hmC in genomic DNA to 
specifically elucidate whether hmC is exclusively derived from mC, how hmC 
levels are maintained in proliferating and non-dividing cells, and what are the 
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temporal dynamics between C, mC and hmC in DNA. To address these 
questions in mammalian cells and in an animal, we have used chemical 
isotopic labeling of genomic DNA coupled with ultra-sensitive analytical liquid 
chromatography-tandem mass spectrometry (LCMS).  
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Results and Discussion 
 
Global hmC levels do not change during the cell cycle 
 
Our simple premise for these experiments was that if no hmC is produced 
during DNA replication (the S phase), when the total amount of DNA per cell 
doubles, then a two-fold drop in global hmC levels would be observed. To 
explore the timing of hmC formation, relative to replication, we set out to 
quantify hmC levels in genomic DNA in a synchronized population of cultured 
cells at defined points during the cell cycle. A robust LCMS assay (Fig. 1a and 
Supplementary Fig. S1) was used to quantify global levels of mC and hmC in 
the DNA of colorectal cancer (HCT116) and breast cancer (MCF7) cells. The 
asynchronous cell population was treated with a high dose of thymidine, 
arresting the cells in G1/S interphase, released into a thymidine-free medium 
and allowed to progress through one cell cycle (double-thymidine 
synchronization21) (Supplementary Fig. S2). In agreement with previous 
studies22,23, we measured mC levels to be constant throughout the cell cycle, 
consistent with restoration of the correct methylation pattern on the nascent 
strand during DNA replication (Fig. 1b). We found that hmC content is also 
uniform throughout one cell cycle in synchronized HCT116 and MCF7 cells. 
Both cell lines unexpectedly showed an increase in global hmC levels 
immediately after thymidine treatment (2.7- and 1.5-fold, P = 0.0003 and 
0.001 for HCT116 and MCF7, respectively) (Supplementary Fig. S3), which is 
consistent with observations reported by Otani et al. in mES cells24. As a 
complementary approach to establish cell-cycle dependence of hmC, HCT116 
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and mES cells were fixed and stained with propidium iodide, then sorted by 
fluorescence activated cell sorting (FACS), according to the DNA content, into 
G1, early S, late S and G2/M phases. This confirmed that there are no major 
changes in global hmC levels during the cell cycle (Fig. 1c; Supplementary 
Fig. S4). Given there was not a two-fold decrease in hmC levels after 
replication, these data suggested that mC oxidation may be occurring during 
DNA replication (S phase) on either the nascent or the template strand.  
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Figure 1. Global levels of mC and hmC do not change during the cell 
cycle. 
 
(a) An overview of the LCMS method for quantification of modified cytosines. 
Genomic DNA, isolated from cells, is digested in a single step with a mixture 
of enzymes to generate 2’-deoxynucleosides, which are separated on an ultra 
high performance liquid chromatography (UHPLC) column and quantified 
using tandem mass spectrometry. The levels of mC and hmC are expressed 
as a percentage of total cytosines. For calibration curves see Supplementary 
Figure S1. (b) Global levels of mC and hmC present in DNA isolated from 
HCT116 and MCF7 cells arrested in G1/S interphase and allowed to progress 
through one cell cycle. The shaded background indicates in which phase the 
majority of cells was found by fluorescence activated cell sorting (FACS) 
analysis (Supplementary Fig. S2). Shown are mean ± SEM of 3 and 2 
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biological replicates for HCT116 and MCF7, respectively, and at least 2 
technical replicates per sample. (c) Global mC and hmC levels in HCT116 
and mES cells sorted by the DNA content into G1/0, early S, late S and G2/M 
phases. Shown are mean ± SEM of 2 biological and 2 technical replicates per 
sample. See also Supplementary Figure S4. 
 
hmC is generated on a newly synthesized DNA strand with a time delay 
 
To address the timing of hmC formation on nascent DNA we set out to isolate 
DNA at different time points post-replication.  We initially attempted to 
incorporate 5-bromo-2’-deoxyuridine (BrdU) during replication followed by 
isolation of newly replicated DNA with an anti-BrdU antibody.25,26 However, 
this approach failed as the anti-BrdU antibody also enriches for hmC (13-fold 
in a negative control containing no BrdU) (Supplementary Fig. S5). We 
therefore designed a strategy based on feeding cells with L-methionine-
(methyl-13C,d3), the major methyl donor to mC via S-adenosylmethionine 
(SAM)-mediated alkylation by a DNA methyltransferase enzyme, to label 
newly synthesized mC and enable monitoring the kinetics of hmC formation in 
genomic DNA by LCMS (Fig. 2a). The light and heavy molecular species are 
clearly distinguishable in the LCMS analysis, allowing accurate and 
reproducible quantification of the labeling ratio (i.e. measured ratio of labeled 
hmC to total hmC (% hmC*)) (Fig. 2b; Supplementary Table S1). Firstly, 
HCT116, MCF7 and mES cells were cultured in heavy medium until a labeling 
plateau was obtained for both cytosine modifications. The measured ratio of 
labeled hmC to total hmC (% hmC*) was smaller than the ratio of labeled mC 
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to total mC (% mC*) until a plateau was reached (Fig. 2c), which is consistent 
with label first being incorporated into mC that is then transformed directly into 
hmC by oxidation. We also observed a delay in hmC labeling in all cell lines 
(e.g. 10-20% hmC* when mC reaches 50% labeling). Thus, there is a lag in 
generating hmC from newly formed (labeled) mC. We further confirmed this 
lag using an alternative labeling system with stable isotopes on the cytosine 
ring and not the methyl group (Supplementary Fig. S6). Proliferation was not 
affected in labeled cells as judged from growth curves generated by live cell 
imaging (Supplementary Fig. S7), therefore we saw no evidence of a kinetic 
isotope effect associated with cleavage of the C-D bond. 
To obtain the exact difference in timing between DNA methylation and the first 
oxidation of mC to hmC in newly replicated DNA, we looked for the initial 
emergence of labeled hmC species in DNA from cells grown with L-
methionine-(methyl-13C,d3) for up to 10 h. The detection limit of our LCMS set-
up is in the low attomole range, which corresponds to 1 in 107 bases or about 
1 in 500 hmCs in HCT116, 1 in 2000 hmCs in MCF7 and 1 in 6000 hmCs in 
mES cells when 100 ng of DNA is digested (Supplementary Fig. S8). We 
found that, in the human cancer cells and mES cells, it takes more than 4 h 
and 2 h, respectively, for the first detectable labeled hmC to appear in 
replicated DNA, and that this species initially builds up very slowly (Fig. 2d; 
Supplementary Fig. S9). This indicates that maintenance of hmC differs from 
mC in dividing cells.  Most mC oxidation therefore does not occur on the 
nascent strand during DNA synthesis, and hemi-hydroxymethylated sites 
must form in the double-stranded DNA produced immediately after replication.
 10 
Figure 2. DNA methylation and mC oxidation activities occur with a 
marked time difference. 
 
(a) An overview of the labeling strategy for measuring the timing of mC 
oxidation. Cells were grown in a medium containing L-methionine-(methyl-
13C,d3), which leads to incorporation of stable isotopes into newly formed mCs 
in genomic DNA via S-adenosylmethionine (SAM). Subsequent LCMS 
analysis using accurate masses of labeled and unlabeled species provides 
mC and hmC labeling ratios (% mC* and hmC*). This in turn allows following 
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the formation of hmC on a newly methylated DNA. (b) An example of 
extracted ion chromatograms from a DNA digest from mES cells labeled with 
L-methionine-(methyl-13C,d3) showing all analytes (heavy and light mC and 
hmC), and their corresponding retention times and mass transitions. The 
coefficient of variation for 3 technical replicates is typically less than 2%. MS 
signal intensity (arbitrary units) is shown on the y axis. (c) HCT116, MCF7 and 
mES cells were grown in the heavy medium for more than 14 days. The gap 
between mC and hmC labeling curves reveals that there is a timing difference 
between mC formation and its oxidation to hmC. (d) Detailed analysis of the 
first 10 h of labeling shows that in cancer cell lines and mES cells, it takes at 
least 4 h and 2 h, respectively, to begin oxidizing newly methylated DNA. 
Shown are mean and S.E.M. from 2 biological replicates (HCT116 and mES) 
or 2 technical replicates (MCF7). See also Supplementary Figures S8 and S9 
for the detection limits of our LCMS, and more biological replicates for 
HCT116 and MCF7 cells. 
 
The majority of hmC in genomic DNA is stable in cultured cells and in vivo 
 
To measure how long mC and hmC persist in DNA and if they are removed 
via enzymatic transformation, we cultured HCT116 and MCF7 cells in the 
heavy (L-methionine-(methyl-13C,d3)) medium for 2 h to label a small 
population of mC (4-9%), and continued the culture in light medium for several 
days. In both studied cell lines, the hmC labeling curve is the steepest 
between 10-25 h, showing that the majority of hmC is formed from mC that is 
on average 10-25 h old (Fig. 3a, Supplementary Fig. S10). Such timing 
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overlaps with the S phase of the next cell cycle, and therefore shows that 
there must be some DNA oxidation activity on the template strand. This effect 
will also be responsible for hiding any global hmC variations in synchronized 
cells, as during the release from G1/S there will still be oxidation activity on the 
DNA synthesized prior to the second thymidine block, or in sorted cells as 
shown in Figure 1 and by Otani et al.24. 
After this initial DNA oxidation activity, both heavy mC and hmC species 
remain present in DNA for more than 5 days, and the labeling ratios (%mC* 
and %hmC*) only decrease due to cell proliferation (i.e. adding more 
unlabeled mC and hmC into the population). We cannot completely rule out 
that small quantities of heavy hmC are not gradually generated from the 
relatively large pool of heavy mC, and subsequently removed. However, as 
cells become confluent leading to growth arrest and no more DNA is 
produced in the system, the labeling curves flatten (e.g. HCT116 past t = 60 
h), strongly suggesting that the majority of both mC and hmC is long-lived or 
static in DNA of cultured differentiated cells (Fig. 3a and Supplementary Fig. 
S10). We have observed the same labeling profiles in undifferentiated mES 
cells, and also in mES cells which were allowed to differentiate at the start of 
labeling (Fig. 3b). 
To explore the timing of mC oxidation and the stability of hmC in vivo, we 
generated mice comprising isotopically labeled mC and hmC in their genomic 
DNA. We fed a breeding pair of wild-type mice with a custom diet in which all 
L-methionine was replaced with L-methionine-(methyl-13C,d3). After 4 months 
(117 d), we measured the labeling efficiency of mC and hmC in the genomic 
DNA across a range of tissues by LCMS. We obtained a high labeling 
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percentage (40-60% mC*) in the fast proliferating thymus and gut, lower 
levels (5-10% mC*) in kidney and heart, and only 0.2% and 2.9% mC* in the 
female and male cerebellum, respectively (Fig. 3c). It is noteworthy that brain 
DNA has the highest global hmC level of up to 0.7% of total cytosines4, and 
therefore the low levels of newly incorporated labeling in hmC (and mC) 
provide the first evidence that most of these modifications are stable in DNA 
in vivo. Similar to the cell culture experiments described in Figure 2, % mC* 
was higher than % hmC* in DNA from all adult tissues (Fig. 3c). If hmC were a 
transient intermediate, its labeling ratio would have to be equal to the labeling 
ratio of mC (the system would be in a steady state). Therefore, the majority of 
hmC must be stable also in these remaining tissues. 
We did not observe any differences in mC and hmC labeling in developing 
tissues of pups that were born during the course of the above experiment (Fig. 
3d and Supplementary Fig. S11). This indicates that the pool of labeled and 
unlabeled methyl donors in the female blood has reached equilibrium prior to 
fertilization and development of the pups. Consequently, the difference 
between % mC* and hmC* in proliferating adult tissues can only be explained 
by the presence of a non-proliferating (and therefore unlabeled) cell 
population with high hmC content, alongside a proliferating (labeled) cell 
population with relatively lower hmC content (Supplementary Fig. S12). This 
is consistent with our findings about the relationship between global hmC 
levels and proliferation (see below). 
TET1 has been found to play a role in active DNA demethylation and memory 
formation in adult mouse brain27,28, therefore we also generated labeled mice 
deficient in one or both copies of the gene encoding the TET1 dioxygenase to 
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determine the influence of TET1 on the lifetime of hmC. We fed a breeding 
pair of heterozygous Tet1tm1.1Jae mice29, each carrying one functional and one 
non-functional Tet1 allele, starting from the last week of pregnancy. After birth 
(a litter of 3 wild-type (WT, normal TET1), 4 heterozygous (Het, one functional 
copy of TET1) and 3 homozygous (Hom, no functional TET1) pups), the 
family was fed for 6 more days before measuring the labeling efficiency of mC 
and hmC in the genomic DNA across a range of tissues (Supplementary 
Figure S13). 
Consistent with published work29, TET1 Hom pups had a slightly reduced 
weight relative to their WT littermates (1.3-fold, P = 0.01), and they 
incorporated correspondingly fewer isotopic labels into mC in all studied 
tissues (Supplementary Figs S14 and S15). Importantly, our data shows that 
the labeling ratio of hmC (% hmC*) or global levels of hmC do not significantly 
differ between WT and Hom pups (Supplementary Figs S15 and S16). This 
result indicates that the absence of TET1 does not impair the conversion of 
mC to hmC in any of the studied tissues, during the last and first week of pre- 
and postnatal development. 
The observations about hmC stability are consistent with the studies in the 
early mouse development, where some hmC formed on the paternal genome 
in the zygote has been shown to be stable for several cell divisions and to 
disappear only due to the lack of maintenance during DNA replication30-34. 
However, this type of DNA demethylation, also called “active modification – 
passive removal”, differs from our observations in adult and developing 
tissues, where hmC is actively placed on new DNA with a time delay, and 
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then remains stable, and therefore the removal of mC (demethylation) cannot 
be its sole function in DNA. 
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Figure 3. The majority of genomic hmC is stable.  
 
(a) Asynchronous HCT116 and MCF7 cells were labeled with L-methionine-
(methyl-13C,d3) for 2 h and then grown in a light medium for several days. The 
bulk of hmC is derived from mC that is 15-25 h old, and persists in the 
genome until the labeling ratio gets diluted due to proliferation (i.e. generation 
of more unlabeled hmC). Dotted lines represent mC and hmC labeling in 
HCT116 cells that grew to confluency and stopped dividing, showing how 
stable the majority of hmC is in DNA. Shown are mean ± SEM of 2-3 technical 
replicates between 3-14 h of the experiment. The coefficient of variation 
between technical replicates is typically less than 2%. See also 
Supplementary Figure S10 for 6 and 10 h pulses in HCT116. (b) Labeling of 
undifferentiated and differentiating mES cells shows similar mC and hmC 
labeling profiles as for the differentiated cancer cells in (a). Shown are mean ± 
SEM of 2 technical replicates. Single replicate is shown for hmC in 
undifferentiated mES cells. (c) A breeding pair of wild-type animals was fed 
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with a diet containing L-methionine-(methyl-13C,d3) for 117 days, and a range 
of tissues was analyzed by LCMS. The low labeling efficiency in slowly 
dividing and non-dividing tissues indicates that the majority of both mC and 
hmC must be stable in vivo. Gut-SI = small intestine. Shown are mean ± SEM 
of 2 technical replicates. See also Supplementary Figure S12. (d) mC and 
hmC labeling ratios in newborns (1 d old, parents labeled for 52 d before 
fertilization). Shown are mean ± SEM of 2 pups. 
 
Cell proliferation is a major determinant of global hmC levels in vivo 
 
We next plotted the global levels of hmC in genomic DNA against proliferation 
of the corresponding tissue, as determined by the incorporation of stable 
isotopes from L-methionine-(methyl-13C,d3) to mC, and found a linear 
correlation in all examined WT adult tissues apart from the brain (Fig. 4a). The 
brain is mostly a non-dividing tissue and therefore cannot follow this 
relationship. Antibody staining for hmC and the proliferation marker Ki67 in 
formalin-fixed paraffin-embedded tissue sections confirmed that hmC is 
abundant in the differentiated, non-proliferating cell types of the brain, liver or 
intestinal villi, and is low in proliferating Ki67 positive cells present in the 
splenic germinal centres or the intestinal crypts (Fig. 4b).  
The central findings of our study show that the majority of hmC in genomic 
DNA is stable and that it takes a longer time to establish hmC on a newly 
synthesized DNA strand, in contrast with DNA methylation activity, which 
occurs immediately during replication. On the basis of these results, we 
propose that the average age of DNA (post replicative) in a population (and 
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therefore the proliferation rate) is the major factor governing the global levels 
of hmC in both differentiated and undifferentiated cell types (Fig. 4c). This 
model explains the tissue specific levels of hmC (Fig. 4a), the increased 
global hmC levels in cells treated with either thymidine (Supplementary Fig. 
S3 and Otani et al.24) or a high dose of ascorbic acid (Supplementary Fig S17, 
Minor et al.35 and Blaschke et al.36), the high hmC level found in ‘immortal’ 
DNA strands37 and the reduced levels of hmC reported in all studied cancers5-
7. 
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Figure 4. Isotopic labeling of DNA in vivo confirms the stability of hmC 
and reveals a relationship between global hmC levels and proliferation.  
 
(a) Linear correlation between proliferation rate (estimated from % mC*) and 
global levels of hmC in tissues from WT adult mice labeled for 117 d (male 
and female). Brain outlier (red) was omitted from the correlation coefficient. 
Shown are mean ± SEM of 2 animals on the y axis (except for prostate and 
testis), and a mean %mC* was used on the x axis. (b) Immunohistochemistry 
for hmC and the proliferation marker Ki67. Shown are details of the dentate 
gyrus in the hippocampus, hepatic triad, splenic germinal centre, crypts and 
villi in the small intestine, and the cortico-medullary junction in the thymus. 
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hmC is abundant in the differentiated, non-proliferating cell types and low in 
proliferating Ki67 positive cells. Horizontal bars indicate 100 µm (1 mm in 
inset image). (c) A model explaining the reduction of global hmC levels in 
faster proliferating cells and tissues compared to slowly proliferating ones (e.g. 
tumour vs. healthy tissue) based on our findings about the timing of DNA 
oxidation and the persistence of hmC in the genome. According to this model, 
the average age of DNA in a population of differentiated cells will be the major 
determining factor of global hmC content. 
 
Conclusions 
 
Since the discovery of hmC in mammalian DNA there has been an emphasis 
on the role of hmC as an intermediate in the mechanism of active 
demethylation. Herein we have presented the first evidence that the majority 
of hmC is actually stable in the genomic DNA of cultured cells and in vivo, 
rather than existing merely as a transient species. Given that hmC is 
particularly enriched in promoters and gene bodies of actively transcribing 
genes13,16-19, we propose that hmC is an epigenetic mark that is distinct from 
mC and therefore likely to have a different regulatory function. Contrary to mC, 
hmC is produced on a new DNA strand slowly and gradually over 30 h in 
cultured cells. Given the temporal stability of hmC in DNA, it will be vital in 
future studies to use methods that distinguish mC from hmC such as oxBS-
seq38 when profiling DNA methylation in the genome. 
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We propose that the timing of mC oxidation during cellular proliferation is 
responsible for reduced levels of hmC in genomic DNA, such as those 
observed during tumorigenesis.  
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Methods 
Cell culture 
HCT116 cells were maintained in McCoy’s 5A medium supplemented with 
10% FBS, penicillin and streptomycin. MCF7 cells were maintained in a 
DMEM medium supplemented with 10% FBS, penicillin and streptomycin. 
mES cells were derived by Dr Xiangang Zou in the CRUK Cambridge Institute 
from a C57BL/6 mouse and cultured on a gelatin-coated plate in a DMEM-KO 
medium (Invitrogen) supplemented with 10% FCS, MEM non-essential amino 
acids, glutamine, sodium pyruvate, penicillin, streptomycin, mouse leukemia 
inhibitory factor (mLIF) and 2i as described by Ying et al.39 For isotopic 
labeling experiments, all cells were maintained in a custom L-methionine-free 
DMEM-KO medium (Invitrogen) supplemented with 30 mg/L of either L-
methionine (Sigma) or L-methionine-(methyl-13C,d3) (Cambridge Isotope), and 
the respective components above. For HCT116 and MCF7 cells, 3 g/L of D-
(+)-glucose was added.  
 
Animals 
All in vivo experiments were performed under the terms of a UK Home Office 
license. C57BL/6 and B6;129S4-Tet1tm1.1Jae/J mice29 (Jackson Labs) were 
bred and housed according to UK Home Office guidelines. Custom L-
methionine-free mouse diet supplemented with L-methionine-(methyl-13C,d3) 
(Sigma) was manufactured by TestDiet. 
 
Genomic DNA extraction 
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Cells and tissues were resuspended in lysis buffer (100 mM Tris, pH 5.5, 5 
mM EDTA, 200 mM NaCl, 0.2% SDS) supplemented with 400 μg/ml 
proteinase K (Invitrogen) and 200 μg/ml RNase A (Qiagen), and were 
incubated at 55°C overnight. DNA was purified using 
phenol:chloroform:isoamyl alcohol (25:24:1, Sigma) and Phase Lock Gel (5 
Prime), precipitated from 70% ethanol and resuspended in ultrapure HPLC-
grade water. 
 
DNA degradation to 2’-deoxynucleosides and LCMS analysis 
Up to 500 ng of DNA was incubated with 5 U of DNA Degradase Plus (Zymo 
Research) for 4 h at 37°C. Samples were filtered through a pre-washed 
Amicon 10 kDa centrifugal filter unit (Millipore) before LCMS analysis (filtration 
step for the Q-Exactive instrument only, see below).  
 
LCMS analysis of global mC and hmC levels 
Analysis of global levels of mC and hmC was performed on an AB Sciex 
Triple Quad 6500 mass spectrometer fitted with an Agilent Infinity 1290 LC 
system and an Acquity UHPLC HSS T3 column (50  2.1 mm, 1.8 µm particle 
size) at a flow rate of 300 µl/min, and a gradient of 0.1% formic acid in water 
and acetonitrile. Calibration curves were generated using a mixture of 
synthetic standards 2’-deoxycytidine (Sigma), 5-methyl- and 5-hydroxymethyl-
2’-deoxycytidine (Berry&Associates), in the ranges of 0.01 – 100 µM, 0.0005 
– 5 µM and 0.0001 – 1 µM for C, mC and hmC respectively. Samples and 
synthetic standards were spiked with an isotopically labeled mix containing 1 
µM of 2’-deoxycytidine-(15N,d2) (synthesis and characterization in 
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Supplementary Methods), 5-methyl-2’-deoxycytidine-(d3) and 5-
hydroxymethyl-2’-deoxycytidine-(d3) (both Toronto Research Chemicals). The 
mass spectrometer was operated in multiple reaction monitoring (MRM) with 
transitions 228-112, 242-126, 258-142, 231-115, 245-129, 261-145 for C, mC, 
and hmC and their internal standards, respectively. The ion source was 
electrospray in positive mode. Results are expressed as a % of total cytosines. 
 
LCMS analysis of isotope incorporation into genomic DNA 
Analysis of isotope incorporation into DNA was performed on a Q-Exactive 
mass spectrometer (Thermo) fitted with an UltiMate 3000 RSLCnano HPLC 
(Dionex) and a self-packed hypercarb column (20 mm  75 µm, 3 µm particle 
size) at a flow rate of 0.75 µl/min, and a gradient of 0.1% formic acid in water 
and acetonitrile. For labeling work with L-methionine-(methyl-13C,d3), ions of 
masses 228.1, 242.1, 246.1, 258.1 and 261.1 (corresponding to C, mC, mC*, 
hmC and hmC*, respectively) were fragmented in a positive ion mode at 10% 
normalized collision energy, and full scans (50 - 300 Da) were acquired for 
each channel. Extracted ion chromatograms of base fragments (112.0505, 
126.0661, 130.0884, 142.0611 and 145.0770 +/- 5 ppm, respectively) were 
used for quantification. Results are expressed as % labeling (e.g. % mC* 
stands for labeled mC over total mC). 
 
Supplementary Methods 
Cell synchronization experiments, vitamin C treatments, FACS analysis of cell 
cycle, cell sorting by the DNA content, BrdU immunoprecipitation, 
 25 
immunohistochemical stainings of mouse tissue sections and chemical 
synthesis are described in Supplementary Methods. 
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